Kamada Ltd., a global biopharmaceutical company specializing in plasma-derived therapeutics, is expanding its plasma collection capabilities with a new facility in San Antonio, Texas. The 11,100-square-foot center is designed to support up to 50 donor beds and is projected to collect up to 50,000 liters of plasma annually.
The new site will focus on collecting specialty hyper-immune plasma, which contains high concentrations of specific antibodies used to combat various infections and diseases. These include treatments for conditions such as rabies exposure, hepatitis B, and complications following organ transplantation.
CEO Amir London emphasized the strategic importance of the facility, noting that it will help reduce raw material costs and decrease dependency on third-party plasma suppliers. Once fully operational, the center is expected to generate between $8 million and $10 million in annual revenue from normal source plasma sales.
Pending approval from the U.S. Food and Drug Administration and European Medicines Agency, which is anticipated within nine to twelve months, the facility represents a significant step in Kamada's expansion of plasma therapeutic capabilities. The company already has FDA approval for six plasma-derived therapeutics targeting rare and underserved medical conditions.
This expansion follows Kamada's recent opening of a similar facility in Houston and builds upon its existing plasma collection center in Beaumont, Texas. By developing its own collection infrastructure, Kamada is positioning itself as a potential major player in the specialty plasma-derived therapeutics market.
